

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16A




FIG. 16B




FIG. 17




FIG. 18




FIG. 19




FIG. 20A




FIG. 20B




FIG. 21A






FIG. 21B SK-OV3 tumor cell Lysis



Ab ID	TY24051	TY24052	TY25023	TY25026	Ref-CD3 x Isotype control
EC50 (ng/mL)	0.057	102.4	0.054	2781	99.04

FIG. 21C IFN- γ secretion of activated CD8⁺T Cells



Ab ID	TY24051	TY24052	TY25023	TY25026	Ref-CD3 x Isotype control
EC50 (ng/mL)	0.137	173.1	0.081	5381	117

Cytokine Release in Cynomolgus Monkeys Treated with bsAbs




FIG. 22A




FIG. 22B




FIG. 23

Absolute Lymphocyte Count After Treatment with SAFE and non-SAFE bsAbs




FIG. 24A




FIG. 24B




FIG. 24C

Plasma concentration (raw data)

Time(h)	Conc.(µg/mL)											
	Sample No. #1001 FG12940				TY24052				TY25023			
	0.2mpk	0.5mpk	0.9mpk	1.65	0.2mpk	0.5mpk	0.9mpk	1.65	0.2mpk	0.5mpk	0.9mpk	1.65
0	<LLOD	1.22	5.83	1.65	<LLOD	1.22	5.83	1.65	<LLOD	1.22	5.83	1.65
0.25	4.38	13.82	30.10	37.26	4.38	13.82	30.10	37.26	4.38	13.82	30.10	37.26
1	4.27	12.11	26.83	25.55	4.27	12.11	26.83	25.55	4.27	12.11	26.83	25.55
8	2.68	10.61	23.38	22.00	2.68	10.61	23.38	22.00	2.68	10.61	23.38	22.00
24	2.12	7.92	18.38	17.89	2.12	7.92	18.38	17.89	2.12	7.92	18.38	17.89
48	1.91	7.16	16.73	17.71	1.91	7.16	16.73	17.71	1.91	7.16	16.73	17.71
72	1.66	6.76	13.09	15.61	1.66	6.76	13.09	15.61	1.66	6.76	13.09	15.61
96	1.43	7.30	15.78	14.38	1.43	7.30	15.78	14.38	1.43	7.30	15.78	14.38
168	1.22	5.83	12.79	11.65	1.22	5.83	12.79	11.65	1.22	5.83	12.79	11.65

PK parameters analyzed by DAS3.0

Parameters & units	TY24052				TY25023				TY25026			
	0.2mpk	0.5mpk	0.9mpk	1.65	0.2mpk	0.5mpk	0.9mpk	1.65	0.2mpk	0.5mpk	0.9mpk	1.65
	291	1211	2693	2635	291	1211	2693	2635	291	1211	2693	2635
AUC(0-∞) mg L ⁻¹ h	443	4725	8350	6490	443	4725	8350	6490	443	4725	8350	6490
AUC(0-24) mg L ⁻¹ h	114.15	416.20	302.56	229.54	114.15	416.20	302.56	229.54	114.15	416.20	302.56	229.54
C _{max} mg/L	4.38	13.82	30.10	27.26	4.38	13.82	30.10	27.26	4.38	13.82	30.10	27.26

FIG. 24D




FIG. 24E

Absolute Lymphocyte Count After Treatment with bsAbs




FIG. 24F




FIG. 25A




FIG. 25B




FIG. 26

FIG. 27A





FIG. 27B






FIG. 28

FIG. 29A




FIG. 29B





FIG. 29C






FIG. 30




FIG. 31




FIG. 32

FIG. 33A




FIG. 33B





FIG. 33C






FIG. 34B




FIG. 34A




FIG. 35A




FIG. 35B




FIG. 35C

	Human CD3DE		Monkey CD3DE	
	ELISA EC50 (nM)	Biacore KD (nM)	ELISA EC50 (nM)	Biacore KD (nM)
TY24051	2.034	2.55	0.90	3.81
TY25023	110.6	51.47	22.5	104.4
Ratio	54	20	25	27

FIG. 36A




FIG. 36B





FIG. 36C


Human CD3DE Biacore KD



Sample ID	k_a (1/Ms)	k_d (1/s)	KD (nM)
TY24051	2.289E+06	5.835E-03	2.550
TY25023	1.437E+05	7.395E-03	51.47

FIG. 36D

Monkey CD3DE Biacore KD



Sample ID	k_a (1/Ms)	k_d (1/s)	KD (nM)
TY24051	1.599E+06	6.094E-03	3.812
TY25023	1.940E+05	2.027E-02	104.5

FIG. 36E




FIG. 37A




FIG. 37B




FIG. 37C




FIG. 37D




FIG. 38A




FIG. 38B




FIG. 38C




FIG. 39A




FIG. 39B





FIG. 40



Antibody	TAC2392	TAC2415	TY25455	TY25606	TY25715	TY25716	Isotype Ctrl
EC50(nM)	0.066	0.035	0.031	27.96	0.081	NA	NA

FIG. 41A




FIG. 41B




FIG. 42A




FIG. 42B





FIG. 43B

FIG. 43A



	Human CD4+ T cell EC50 (nM)	Human CD8+ T cell EC50 (nM)	Human B cell EC50 (nM)	Monkey B cell EC50 (nM)
TAC2392	62.1	119.8	NA	NA
TY25455	NA	27.32	NA	39.1

FIG. 44

EMT6-HER2 Breast Cancer Model




FIG. 45




FIG. 46




FIG. 47




FIG. 48




FIG. 49A




FIG. 49B




FIG. 50A




FIG. 50B




FIG. 50C




FIG. 50D




FIG. 51A




FIG. 51B




FIG. 51C




FIG. 52A




FIG. 52B




FIG. 52C




FIG. 53A






FIG. 53B






FIG. 55A




FIG. 55B




FIG. 55C




FIG. 56A






FIG. 56B

**FIG. 57A****FIG. 57B**




FIG. 58




FIG. 59




FIG. 60




FIG. 61




FIG. 62




FIG. 63




FIG. 64A

MC38-HER2 Rechallenge




FIG. 64B




FIG. 65